Topics Related to Division of Health Benefits
Effective with date of service April 17, 2023, NC Medicaid covers bevacizumab-adcd injection, for intravenous use (Vegzelma)
Effective with date of service April 21, 2023, NC Medicaid covers paclitaxel protein-bound particles for injectable suspension, (albumin-bound)
Effective May 30, 2023, NC Medicaid covers aripiprazole extended-release injectable suspension, for intramuscular use (Abilify Asimtufii).
Updates include updated policies on Acuity Tiers, Acuity-Based Contacts and Contact Monitoring.
This bulletin provides details on coverage for COVID-19 Vaccines and COVID-19 Counseling after the ending of the Federal Public Health Emergency.
The North Carolina Department of Health and Human Services recently awarded Acentra Health the contract as the Comprehensive Independent Assessment Entity (CIAE) for NC Medicaid. Acentra Health will provide management and oversight for the Preadmission Screening Resident Review (PASRR) Level II process and will also serve as the Local Contact Agency (LCA), responsible for providing interested Nursing Facility (NF) residents with options for transitioning from institutional care to community-based living.
Effective July 1, 2023, NC Medicaid has increased the Medicaid rate for Maternal Bundled Payments for pregnancy care.
A draft application for § 1915 (c) NC Innovation Waiver is posted for a 30-day public comment period.
The report and instructions for completing the report are updated to capture additional information needed for Credit Balance Audits
Effective Jan. 1, 2023, the location field must have a valid value of 1 or 2.